Literature DB >> 18177343

Genetic detoxification of an aroA Salmonella enterica serovar Typhimurium vaccine strain does not compromise protection against virulent Salmonella and enhances the immune responses towards a protective malarial antigen.

Nicola D McKelvie1, Shahid A Khan, Michail H Karavolos, David M Bulmer, Jeong Jin Lee, Raquel DeMarco, Duncan J Maskell, Fidel Zavala, Carlos E Hormaeche, C M Anjam Khan.   

Abstract

Live Salmonella vaccines are limited in use by the inherent toxicity of the lipopolysaccharide. The waaN gene encodes a myristyl transferase required for the secondary acylation of lipid A in lipopolysaccharide. A waaN mutant exhibits reduced induction of the inflammatory cytokines associated with lipopolysaccharide toxicity. Here the characteristics of a Salmonella enterica serovar Typhimurium aroA waaN mutant (SK100) in vitro and in vivo compared with its parent aroA strain (SL3261) were described. Phenotypic analysis of purified lipopolysaccharide obtained from SK100 confirmed that the physical and biological activities of the lipopolysaccharide had been altered. Nevertheless both strains had similar patterns of colonization and persistence in mice and significantly the aroA waaN mutant was equally as effective as the parent at protecting against challenge with wild-type S. Typhimurium. Furthermore, a SK100 strain was constructed expressing both tetanus toxin fragment C and the circumsporozoite protein of a malaria parasite. In marked contrast to its isogenic parent, the new attenuated strain induces significantly enhanced immune responses against the circumsporozoite protein. The waaN mutation enhances the ability of this strain to elicit immune responses towards guest antigens. This study provides important insights into the development of safe and effective multivalent Salmonella vaccines.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18177343     DOI: 10.1111/j.1574-695X.2007.00368.x

Source DB:  PubMed          Journal:  FEMS Immunol Med Microbiol        ISSN: 0928-8244


  6 in total

Review 1.  New technologies in developing recombinant attenuated Salmonella vaccine vectors.

Authors:  Shifeng Wang; Qingke Kong; Roy Curtiss
Journal:  Microb Pathog       Date:  2012-11-08       Impact factor: 3.738

2.  Oral immunization with attenuated Salmonella enterica serovar Typhimurium encoding Cryptosporidium parvum Cp23 and Cp40 antigens induces a specific immune response in mice.

Authors:  Alvaro J Benitez; Nina McNair; Jan R Mead
Journal:  Clin Vaccine Immunol       Date:  2009-07-15

Review 3.  The next frontier of oncotherapy: accomplishing clinical translation of oncolytic bacteria through genetic engineering.

Authors:  Kaitlin M Dailey; JuliAnne E Allgood; Paige R Johnson; Mackenzie A Ostlie; Kambri C Schaner; Benjamin D Brooks; Amanda E Brooks
Journal:  Future Microbiol       Date:  2021-03-23       Impact factor: 3.165

4.  Aptamer-assisted tumor localization of bacteria for enhanced biotherapy.

Authors:  Zhongmin Geng; Zhenping Cao; Rui Liu; Ke Liu; Jinyao Liu; Weihong Tan
Journal:  Nat Commun       Date:  2021-11-15       Impact factor: 14.919

5.  Safety of the Salmonella enterica serotype Dublin strain Sdu189-derived live attenuated vaccine-A pilot study.

Authors:  Fuzhong Wang; Lei Wang; Haojie Ge; Xiaobo Wang; Yaxin Guo; Zhengzhong Xu; Shizhong Geng; Xin'an Jiao; Xiang Chen
Journal:  Front Vet Sci       Date:  2022-09-28

6.  msbB deletion confers acute sensitivity to CO2 in Salmonella enterica serovar Typhimurium that can be suppressed by a loss-of-function mutation in zwf.

Authors:  Verena Karsten; Sean R Murray; Jeremy Pike; Kimberly Troy; Martina Ittensohn; Manvel Kondradzhyan; K Brooks Low; David Bermudes
Journal:  BMC Microbiol       Date:  2009-08-18       Impact factor: 3.605

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.